During the past decade, ULSS2 Marca Trevigiana conducted 10 clinical trials. In the 10-year time frame, 10 clinical trials started and 1 clinical trials were completed, i.e. on average, 10% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 1 clinical trials were completed. i.e. 11.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "ULSS2 Marca Trevigiana" #1 sponsor was "Bayer" with 2 trials, followed by "ETOP IBCSG Partners Foundation" with 2 trials sponsored, "Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori" with 2 trials sponsored, "University of Padova" with 2 trials sponsored and "Edwards Lifesciences" with 2 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "ULSS2 Marca Trevigiana" #1 collaborator was "AstraZeneca" with 1 trials as a collaborator, "Azienda Ospedaliera di Padova" with 1 trials as a collaborator, "Azienda Ospedaliero-Universitaria di Parma" with 1 trials as a collaborator, "Azienda Ulss 2 Marca Trevigiana" with 1 trials as a collaborator and "CINECA consorzio universitario italiano" with 1 trials as a collaborator. Other collaborators include 9 different institutions and companies that were collaborators in the rest 19 trials.

According to Clinical.Site data, the most researched conditions in "ULSS2 Marca Trevigiana" are "Acute Lymphoblastic Leukemia" (1 trials), "Acute Myeloid Leukemia" (1 trials), "Anesthesia Brain Monitoring" (1 trials), "Aortic Stenosis" (1 trials) and "Aortic Valve Stenosis" (1 trials). Many other conditions were trialed in "ULSS2 Marca Trevigiana" in a lesser frequency.

Most popular intervention types in "ULSS2 Marca Trevigiana" are "Drug" (6 trials), "Device" (2 trials), "Biological" (1 trials), "Genetic" (1 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Anti-CD22 Immunotoxin" (1 trials), "Apixaban" (1 trials), "Apixaban matching placebo" (1 trials), "Asundexian (BAY2433334)" (1 trials) and "Asundexian matching placebo" (1 trials). Other intervention names were less common.

The vast majority of trials in "ULSS2 Marca Trevigiana" are 9 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "ULSS2 Marca Trevigiana". undefined are not yet recruiting, 4 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in ULSS2 Marca Trevigiana, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in ULSS2 Marca Trevigiana, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".

ULSS2 Marca Trevigiana has several departments that took part in Clinical trials: "Azienda U.L.S.S.9 - U.O. di Ematologia" - 22 trials, "Ospedale di Castelfranco Veneto - Ematologia" - 4 trials, "ULSS2 Marca Trevigiana; UOC Oncologia Medica - Distretto di Treviso" - 4 trials, "Ospedale Santa Maria Dei Battuti - U.O. Di Cardiologia" - 3 trials, "Ospedale Ca' Foncello, U.O.C. Cardiologia" - 2 trials, "Ospedale Ca'Foncello - Pulmonology Department" - 2 trials, "Treviso Regional Hospital" - 2 trials, "Ospedale De Gironcoli" - 2 trials